All In Biotech

Drug Trial Radar · NCT00924703

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU

Last checked: Nov 20, 2026Latest source record: Oct 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

68

Actual

Start

Jan 13, 2010

Primary completion

Jan 31, 2019

Study completion Jan 31, 2019

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jun 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.

Conditions

  • Phenylketonuria

Interventions

  • rAvPAL-PEGDrug

    The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Blood Phenylalanine (Phe) ConcentrationTime frame: At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The Children's Hospital

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Ann and Robert H Lurie Children's Hospital

    Chicago, Illinois

  • University of Louisville, Kosair Charities Pediatric Clinical Research Unit

    Louisville, Kentucky

  • Children's Hospital Boston

    Boston, Massachusetts

  • University of Missouri

    Columbia, Missouri

  • Washington University Center for Applied Research Sciences

    St Louis, Missouri

  • Nebraska Medical Center

    Omaha, Nebraska

  • Albany Medical Center

    Albany, New York

  • Mount Sinai School of Medicine

    New York, New York

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • University of Utah Hospital

    Salt Lake City, Utah

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.